Comparative Pharmacology
Head-to-head clinical analysis: MERILOG versus MERILOG SOLOSTAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MERILOG versus MERILOG SOLOSTAR.
MERILOG vs MERILOG SOLOSTAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Merilog is a recombinant human insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It also inhibits lipolysis and proteolysis, and enhances protein synthesis.
Insulin glargine is a recombinant human insulin analog that exhibits prolonged duration of action due to slow subcutaneous absorption. It binds to insulin receptors, activating downstream signaling pathways involved in glucose uptake, glycogen synthesis, and lipogenesis.
10 mg orally once daily, with or without food.
0.5 mg subcutaneously once a day.
None Documented
None Documented
The terminal elimination half-life is approximately 18 hours, allowing for once-daily dosing in most patients. In renal impairment (CrCl <30 mL/min), half-life is prolonged to >40 hours, requiring dose adjustment.
Terminal half-life is about 24 hours (range 18–30 hours), allowing once-daily dosing.
MERILOG is primarily excreted renally as unchanged drug (85%) and as minor metabolites (10%). Fecal excretion accounts for less than 5%.
Approximately 80% of the dose is excreted renally as unchanged drug, with 20% eliminated via bile/feces.
Category C
Category C
Insulin
Insulin